Flucogyl

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Flucogyl

What is Flucogyl?

Flucogyl is a prescription medication designed to address infections caused by fungi and yeasts throughout the body. Its identity is defined by its sole active ingredient, Fluconazole, a key substance within the azole antifungal family, and is manufactured to serve as a versatile systemic treatment.


Quick Facts: Flucogyl (Fluconazole)

Property Description
Active ingredient Fluconazole
Form Capsules, tablets, oral suspension, injection solution
Pharmacological class Triazole Antifungal Agent
Common use Systemic management of fungal and yeast infections
Origin Synthetic compound

Flucogyl: Identity, Composition, and Origin

Flucogyl is a chemically manufactured medicinal entity containing Fluconazole as its single active ingredient. The Fluconazole compound is a synthetic triazole, not derived from natural sources, engineered to selectively target fungal pathogens. Fluconazole exhibits high absorption and effective penetration across bodily membranes. This composition allows for manufacturing in multiple dosage forms, including oral forms like capsules and tablets, as well as a sterile injection solution used for intravenous delivery. Its multiple forms ensure therapeutic flexibility, particularly for pediatric patients who may require the liquid oral suspension.

What Pharmacological Class Does Flucogyl Belong To?

Flucogyl is strictly classified as a triazole antifungal agent within the broader azole class. This specialized classification signifies the drug's selective mechanism of action against fungi. Fluconazole is utilized globally for its effectiveness in managing both localized and systemic fungal infections. It is frequently employed in treating serious infections such as candidiasis that has spread internally.

The general therapeutic purpose of Flucogyl is to inhibit the growth of organisms like Candida and Cryptococcus by blocking a vital process called ergosterol synthesis. This fungistatic action halts the pathogen's ability to maintain its cell structure and replicate, ultimately serving to clear the fungal infection and relieve the associated symptoms.

Regulatory References

  1. WHO Essential Medicines List

What side effects are possible with Flucogyl?

Flucogyl (fluconazole) is generally well-tolerated, but like all medicines, it can cause side effects. Understanding potential adverse effects is important for patient safety.

Common Side Effects

These effects are generally mild and may include:

  • Gastrointestinal issues: Nausea, vomiting, diarrhea, or abdominal pain.
  • Headache
  • Dizziness
  • Changes in taste
  • Rash (typically mild)

Serious Adverse Effects (Rare)

While uncommon, certain side effects require immediate medical attention:

  • Severe Liver Toxicity: Symptoms may include unusual tiredness, dark urine, pale stools, persistent nausea/vomiting, and jaundice (yellowing of the skin or eyes).
  • Serious Skin Reactions: These include potentially life-threatening conditions like Stevens-Johnson syndrome. Signs are a severe, widespread rash, peeling skin, blistering, or mouth/throat sores.
  • Heart Rhythm Problems: Fluconazole may rarely cause changes in heart rhythm (QT prolongation/Torsade de pointes). Report symptoms like a fast or irregular heartbeat, fainting, or severe dizziness.
  • Allergic Reactions: Signs include swelling of the face, lips, tongue, or throat, difficulty breathing, or a severe, itchy rash (hives).
  • Adrenal Insufficiency: Symptoms can include chronic fatigue, muscle weakness, loss of appetite, or nausea.

Safety and Contraindications

Pregnancy and Breastfeeding: Use of Flucogyl during pregnancy, particularly the first trimester, may be associated with an increased risk of miscarriage or birth defects, especially at high doses or with prolonged use. Consult a healthcare provider if you are pregnant, planning to conceive, or breastfeeding.

Pre-existing Conditions: Inform your doctor if you have a history of liver disease, heart rhythm disorders (including prolonged QT interval), or kidney problems, as these conditions may increase the risk of serious side effects.

Overdose and Emergency Response

Overdose and When to Seek Help

This section describes the officially documented clinical signs of overdose, required emergency actions, and supportive procedures as mandated by government regulatory authorities for the active ingredient Fluconazole (contained in Flucogyl).

Domain Official Regulatory Statement
Documented Manifestations Symptoms include hallucinations and paranoid behavior as central nervous system (CNS) effects.
Severe Outcomes The potential for severe acute CNS manifestations, including seizures or convulsions, is officially documented.
Mandatory Action It is required to seek immediate medical attention when an overdose is suspected.

Management is defined as symptomatic and supportive treatment, as regulatory documents state that no specific antidote is known for Fluconazole overdose. Procedural measures for managing overexposure are described in official labeling. These may include gastric lavage and the use of hemodialysis, which is documented to significantly reduce plasma concentrations by approximately 50% in a three-hour session.

Supportive Management Notes

Procedure Regulatory Status
Antidote Availability No specific antidote is known.
Supportive Treatment Symptomatic and supportive treatment is required.
Clearance Hemodialysis can significantly clear the drug from the body.

Therapeutic Uses of Flucogyl

Flucogyl, which contains fluconazole, is considered relevant as an antifungal medication commonly used to help with conditions involving inflammatory or irritative processes caused by fungal pathogens, specifically the Candida and Cryptococcus species. It may be part of symptomatic management across various infection types.

It is used for managing symptoms related to physical discomfort associated with mucosal candidiasis, such as vaginal yeast infections, oral or esophageal candidiasis (thrush), and systemic infections like candidemia, pneumonia, and cryptococcal meningitis. This medication helps address symptom clusters that may become intense or disruptive in serious, systemic infections.

It is also relevant when supportive symptom management is appropriate and may assist with addressing conditions characterized by periods of heightened symptoms (prophylaxis) in patients with compromised immune systems. This provides support that helps ease the overall symptom burden.

Quick Fact: Relief for symptoms related to physical discomfort

“Flucogyl helps address symptom clusters that may become intense or disruptive during flare-ups and provides supportive relief when symptoms interfere with routine activities.”

Eligibility and Restrictions for Use

Who Can and Cannot Use Flucogyl? (Official Regulatory Information)

Eligibility for Flucogyl (Fluconazole) is determined by regulatory agencies based on patient characteristics, pre-existing conditions, and co-administration rules.

Absolute Contraindications

Use of Flucogyl is prohibited (contraindicated) for the following populations as defined in the official labeling:

  • Patients with documented hypersensitivity to Fluconazole, related azole agents, or any product excipients.
  • Patients receiving co-administration of certain medicinal products that prolong the QT interval, specifically Cisapride, Pimozide, and high-dose Terfenadine.

Restricted and Conditional Use

Specific populations are eligible only under restricted use, close monitoring, or mandatory consideration:

Population Group Eligibility Status Basis for Restriction
Renal/Hepatic Impairment Conditional Use Requires monitoring due to elimination and potential for hepatic effects.
Cardiac Conditions Restricted Use Caution required for conditions predisposing to arrhythmia (e.g., severe heart failure, uncorrected electrolyte disturbances).
Pregnancy Contraindicated Except for life-threatening systemic fungal infections. High-dose, chronic use is prohibited.
Lactation Not Recommended Due to excretion into breast milk.
Pediatric Patients Established Use is established but subject to age-specific protocols; oral forms may be contraindicated for certain hereditary sugar intolerances.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Flucogyl (Fluconazole) is formally documented to interact with numerous co-administered medicinal products, primarily due to its documented effect as an inhibitor of the Cytochrome P450 (CYP) enzyme system. Regulatory documents cite Fluconazole as a potent inhibitor of CYP2C9 and CYP2C19, and a moderate inhibitor of CYP3A4, which leads to reduced clearance and increased systemic exposure of many interacting substances.

Contraindicated Combinations

Certain combinations are explicitly prohibited in regulatory labeling due to the heightened risk of serious adverse cardiac events, specifically QT interval prolongation and Torsades de Pointes. These contraindicated substances include Cisapride, Astemizole, Pimozide, Quinidine, and Erythromycin. Terfenadine is also contraindicated at Fluconazole doses of 400 mg/day or higher.

Pharmacodynamic and Exposure Interactions

Co-administration with Coumarin-type anticoagulants (e.g., Warfarin) is associated with an increased Prothrombin Time (INR), raising the potential for bleeding events. Rifampicin exposure results in a reduction of Fluconazole plasma concentration. Conversely, Hydrochlorothiazide administration officially increases Fluconazole exposure. Furthermore, the official label notes that co-administration with food or antacids has no clinically significant effect on Fluconazole absorption. Pharmacokinetics are markedly affected by impaired renal function, which is a key population-specific consideration.

Mechanism of Action

How Flucogyl Works

Flucogyl (Fluconazole) exerts its biological effect via targeted interaction with fungal cell structure. The mechanism is specific to the fungal sterol synthesis pathway, which is distinct from human sterol pathways.

Targeting the Fungal Sterol Synthesis Pathway

The drug's primary action is the selective inhibition of the fungal enzyme 14alpha-demethylase (CYP51). This enzyme is crucial for the ergosterol biosynthesis pathway, which produces ergosterol, an essential sterol component of the fungal cell membrane. By blocking this step, Fluconazole inhibits the synthesis of this essential component.

Disrupting Cell Structure and Causing Fungistasis

Inhibition of the CYP51 enzyme triggers a swift mechanistic cascade. The lack of ergosterol, combined with the toxic buildup of intermediary sterols, compromises the fungal cell membrane, leading to increased permeability and cellular leakage. This molecular disruption arrests the fungus's ability to grow and replicate, an effect known as fungistasis, which is the physiological consequence that halts the fungal pathogen's systemic proliferation.

Understanding Mechanistic Limitations

The mechanism's functional efficacy can be limited at the cellular level by resistance development. Fungi may restrict the drug's action by mutating the ERG11 gene to alter the target CYP51 enzyme, or by overexpressing efflux pumps that actively expel Fluconazole from the cell.

Dosage and Administration Information

Flucogyl (Fluconazole) is administered systemically through two main, therapeutically equivalent routes: the oral route (capsules, tablets, or suspension) and the intravenous (IV) route. The oral medication may be taken independently of food, as its absorption is unaffected by mealtimes. The IV solution must be infused slowly, not exceeding a rate of 10 mL/minute.

The standard administration schedule begins with a loading dose on the first day of treatment, which is generally twice the maintenance dose, designed to rapidly achieve steady therapeutic levels. Maintenance therapy follows as a once-daily dose, with the amount typically ranging from 50 mg to 400 mg. A single 150 mg oral dose is utilized for certain acute conditions. Treatment duration is highly variable, ranging from a single day up to several months for long-term suppressive therapy.

Population-specific adjustments are mandatory for certain patient groups. For adults with renal impairment, the dose must be reduced to 50% of the recommended maintenance dose after the initial loading dose. Pediatric dosing is calculated based on body weight (mg/kg), and the dosing interval is prolonged in neonates. Furthermore, the oral suspension requires reconstitution with water before use and must be shaken vigorously prior to measurement.

Recent Clinical Evidence

Research evidence / Overview of Studies for Flucogyl


Evidence for Mucosal and Superficial Fungal Infections

Research exploring the use of Flucogyl for common conditions like oral, esophageal, and vaginal candidiasis has relied extensively on Randomized Controlled Trials (RCTs). These studies were applied in research contexts involving fluctuating or unstable symptoms. The main focus of these trials was to monitor key outcomes such as the clinical cure rate—meaning the assessment of whether patient-reported discomfort was reduced—and mycological eradication, which tracks the clearance of the fungal organism in laboratory tests. Studies reported that the rate of clinical resolution was observed in the studies in the short-term. However, research describes that for certain patient subgroups with prolonged exposure to antifungal agents, the emergence of decreased fungal susceptibility was associated with the studies.


Evidence for Systemic and Invasive Fungal Disease

Flucogyl was evaluated in research for the management of serious, systemic infections, including candidemia and cryptococcal meningitis. The research base here includes RCTs comparing Flucogyl to alternative antifungal drug classes. Research examined outcomes related to overall survival and fungal clearance from sites like the bloodstream and cerebrospinal fluid (CSF). Data show patterns related to its use as part of a step-down or consolidation regimen after initial therapy. However, for the initial treatment phase of severe infections like cryptococcal meningitis, research describes that using Flucogyl alone was associated with suboptimal microbiological outcomes, meaning that the fungal organism clearance measured in the CSF showed mixed results.


Evidence for Preventing Future Infections (Prophylaxis)

Flucogyl was studied for its role in primary prevention, or prophylaxis, in severely immunocompromised patients. The evidence primarily stems from rigorous RCTs that often compared the drug to a placebo. Findings describe patterns observed in the studies where data show patterns related to a difference in the measured incidence of candidiasis and cryptococcosis between the two study groups. A key research limitation frame is that studies focusing on episodes where symptoms become more noticeable have observed a shift in the fungal species colonizing the patients, which may be less susceptible to the drug. Long-term effects are not fully established regarding the net impact on overall survival across all varied immunocompromised patient groups.

Frequently Asked Questions (FAQ)

Common questions about Flucogyl (FAQ)


Q: Is Flucogyl the same kind of drug as [Commonly confused drug X]?

A: Flucogyl is officially classified as a triazole antifungal agent, a specific type of synthetic medicine used to stop the growth of fungi. This classification defines its specific mechanism of action, which is distinct from other classes of drugs.


Q: Does Flucogyl interact with common over-the-counter pain relievers?

A: Official regulatory documents indicate that Flucogyl may interact with nonsteroidal anti-inflammatory drugs (NSAIDs), a class that includes some common over-the-counter pain relievers. This interaction could potentially affect the concentration of the NSAID in the body.


Q: Is Flucogyl considered a strong or a mild medication?

A: Flucogyl is designated as an Essential Medicine by the World Health Organization (WHO), reflecting its significance in global health. The drug is used for systemic infections that have spread throughout the body, placing it as a key treatment in its therapeutic class.


Q: Why is it described that Flucogyl needs to be used for a long period?

A: The duration of use is highly variable. Long-term use is typically described for severe, specific conditions like cryptococcal meningitis or for suppressive therapy. This extended treatment is intended to prevent the fungal infection from returning in high-risk patients.


Q: Are there specific food items or supplements that are known to interact with Flucogyl?

A: Official information describes that Flucogyl may interact with certain herbal products, specifically mentioning supplements like St. John's Wort. This is due to the drug's documented effect on certain liver enzymes, which may alter how the medicine is processed in the body.


Q: Is Flucogyl safe to use for people over 65 years old?

A: Official documentation indicates that Flucogyl use is established in older adults, though special consideration is given to dosage adjustments in the presence of renal impairment. The need for adjustment is based specifically on kidney function.


Q: Why do official sources sometimes mention Flucogyl with a different drug name?

A: Official sources often refer to the medicine by its active ingredient name, Fluconazole, rather than the brand name Flucogyl. Regulatory bodies and international health organizations, like the WHO, typically use the active ingredient name for clarity and consistency across different regions.


Q: Is the purpose of Flucogyl curative or is it intended for management?

A: Studies and official information indicate that Flucogyl’s purpose spans both short-term clearance and long-term management. It may be used for a single dose for acute infections or over an extended period to prevent the recurrence of fungal disease in certain populations.


Q: What is the risk described in official warnings for Flucogyl?

A: The official product labeling highlights the risk of several serious adverse effects. These risks include severe liver damage, potential for life-threatening skin reactions (e.g., Stevens-Johnson syndrome), and changes to heart rhythm.


Q: Is it true that Flucogyl has been studied for conditions outside of its main approved use?

A: It is described in official data that the drug has been extensively studied, leading to a large clinical data base. This research base includes studies in various patient populations and across a wide range of uses, consistent with a widely studied medicine.


Q: What is the difference between Flucogyl and a supplement often mentioned with it?

A: Flucogyl is regulated as a prescription medicine, meaning regulatory bodies have confirmed its safety and effectiveness based on scientific data. A supplement does not undergo the same pre-market review process for efficacy and safety as an approved drug.


Q: Are there any specific safety monitoring recommendations while using Flucogyl?

A: For patients taking Flucogyl, especially for long periods or with pre-existing conditions, regulatory documents advise the need for specific monitoring. Such monitoring often involves periodic blood tests, which are used to check the status of liver and kidney function.


Q: Why do some people report feeling no difference after starting Flucogyl?

A: The drug's mechanism is described as fungistatic, which means it arrests the fungus's ability to grow rather than rapidly killing the pathogen. Additionally, studies have observed patterns related to decreased fungal susceptibility, which may influence the rate of symptom relief perceived by patients.


Q: How long does it typically take for a person to notice the effects of Flucogyl?

A: The time it takes to see the effects of Flucogyl can depend heavily on the type of infection being addressed. Acute conditions may show improvement within a few days of starting treatment, while severe or systemic infections may require several weeks or months before therapeutic effects are observed.


Q: What should I do if I think I missed a dose of Flucogyl?

A: Official patient information generally describes taking a missed dose as soon as it is remembered. However, if it is close to the time of the next scheduled dose, the instruction is generally to skip the missed dose.


Q: Can I use Flucogyl if I am vegetarian or have dietary restrictions?

A: According to the official product labeling, certain formulations, such as the capsules, may contain gelatin or other inactive ingredients that may not align with strict dietary practices like vegetarianism. The full list of inactive ingredients (excipients) can be reviewed in the package information to confirm compatibility with specific dietary needs.


Q: Are there any known issues with taking Flucogyl and drinking coffee?

A: Regulatory documents indicate that Flucogyl may influence the body’s metabolism of caffeine. This could lead to a buildup of caffeine in the system, potentially increasing related side effects such as feeling nervous or having trouble sleeping.


Q: Is Flucogyl habit-forming or does it have the potential for dependence?

A: Official product information includes a specific statement confirming that Flucogyl is not known to be habit-forming and has no known potential for abuse or dependence.


Q: Does Flucogyl affect sleep patterns?

A: Regulatory documents list insomnia, which is difficulty sleeping, as a potential adverse effect. Any change in sleep pattern, such as insomnia, is listed as an undesirable effect that may occur according to regulatory data.


Q: How long do the effects of one dose of Flucogyl typically last?

A: The drug's elimination is described by its terminal plasma half-life, which is approximately 30 hours in healthy adults. This long half-life is why the drug is generally administered only once a day, as it remains active in the body for an extended duration.


Q: Is Flucogyl available as a generic medicine?

A: Flucogyl is the brand name for the active ingredient, Fluconazole. This active ingredient is available globally as a generic medicine, which has been certified by regulatory agencies as therapeutically equivalent to the brand name version.


Q: Does Flucogyl interfere with common lab tests like blood sugar or cholesterol?

A: According to regulatory information, Flucogyl interacts with certain medicines used to control blood sugar (hypoglycemic agents), which could lead to changes in blood glucose lab values. This possibility is noted as requiring close monitoring of these specific lab parameters.


Q: Why is alcohol listed as a potential interaction with Flucogyl?

A: Regulatory documents advise against combining Flucogyl with alcohol primarily because both substances can independently put stress on the liver. Taking them together may increase the risk of liver-related adverse events and amplify common side effects such as dizziness.


Q: Are there differences between the brand name and generic versions of Flucogyl?

A: Regulatory agencies confirm that generic versions of the active ingredient (Fluconazole) are therapeutically equivalent to the brand name Flucogyl. This means they contain the same active ingredient and are expected to work in the body in the same way.


Q: Does Flucogyl change how someone reacts to sunlight?

A: Official warnings state that Flucogyl can cause the skin to become more sensitive to sunlight, a condition known as photosensitivity. This is described as a rare adverse effect, and protective measures against the sun are sometimes mentioned in association with this warning.


Q: How long does Flucogyl stay in the system after the last use?

A: Based on the drug’s half-life of approximately 30 hours, it typically takes about 6 to 8 days after the last dose for the active ingredient to be almost fully eliminated from the body. This timeline is calculated based on the drug's known half-life.


Q: Are there any special warnings for people with diabetes considering Flucogyl?

A: Regulatory information includes warnings for individuals using diabetes medications. Flucogyl can potentially increase the risk of low blood sugar (hypoglycemia) by altering the effect of certain antidiabetic agents; this possibility is noted as requiring close monitoring.


Q: Does Flucogyl come with a patient medication guide or specific warnings pamphlet?

A: As a prescription medicine with potential serious risks, Flucogyl is typically accompanied by a mandatory Patient Medication Guide or equivalent leaflet. This document is provided to ensure patients receive essential safety information and warnings.


Q: Can a person take Flucogyl if they have a history of seizures?

A: Official regulatory documents list seizures as a rare but serious adverse event associated with the drug. Regulatory warnings indicate that a history of seizure activity is a consideration for use.


Q: Does taking Flucogyl affect the use of hormonal birth control?

A: Official information describes that Flucogyl may influence the blood concentrations of hormones found in oral contraceptives (birth control pills). This interaction may result in changes like spotting or could alter the effectiveness of the contraceptive; regulatory documents note that this interaction may require monitoring.


Q: What makes Flucogyl different from older medications for the same purpose?

A: Flucogyl is known for its high absorption when taken by mouth (oral bioavailability) and its ability to penetrate various body fluids, including the cerebrospinal fluid. This improved distribution is often cited in the research literature as a key difference from older antifungal treatments.


Q: How quickly does Flucogyl get absorbed after ingestion?

A: Official pharmacokinetic information states that when Flucogyl is taken by mouth, the highest concentration in the bloodstream is typically reached between 1 and 2 hours after the dose. This time frame represents the absorption rate of the medicine.

How should Flucogyl be stored and disposed of?

Storage and Handling Requirements

Fluconazole (Flucogyl) must be stored at Controlled Room Temperature, typically between 20 C and 25 C (68 F to 77 F), to maintain product stability. All forms must be stored in their original, tightly closed container and protected from excess moisture and heat. It is mandatory that the liquid forms (oral suspension and intravenous solution) are protected from freezing. The IV solution is designated for single use only and must be used immediately once opened.

Child Safety and Disposal

All medication, including Flucogyl, must be kept out of the sight and reach of children. For disposal, unused or expired product should not be discarded via wastewater or household trash without following specific guidelines. Patients should utilize a drug take-back program or consult a pharmacist regarding proper disposal methods to comply with local environmental regulations.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Flucogyl found in:

A-Z Index: